SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.58+0.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9154)9/18/2003 12:33:28 AM
From: BulbaMan   of 52153
 
>>>...Randomized trials comparing a new regimen against a control or placebo offer the best protection against the risks of erroneous conclusions inherent in phase II trials...<<<

Problem is that it's difficult to recruit patients for randomized clinical trials, especially those involving a placebo because patients fear they will receive the placebo not the new treatment being tested.
Consequently, as pointed out in a two-part NY Times series in 1999 (May 16 & 17), doctors are frequently paid for recruiting patients, with especially ambitious doctors recruiting a disproportionate share of trial participants.
Another 1999 NY Times piece (June 22) reported that a disproportionate number of patients recruited for clinical trials are uninsured and join the trial because they can't afford to pay for the standard treatment.
Both of the above make it very likely that many clinical trials wind up testing a nonrandom sample of subjects, compromising the experimental data.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News